Study of LY3016859 in Participants With Diabetic Nephropathy
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this two-part study is to investigate the safety, tolerability and efficacy of
LY3016859 after multiple intravenous (IV) dosing's in participants with diabetic nephropathy
(DN). Part A will be dose escalation for safety and tolerability and Part B will evaluate
Proteinuria.